- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00620542
CRESTOR Athero Imaging Head to Head IVUS Study (SATURN)
11 de julio de 2012 actualizado por: AstraZeneca
Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
2333
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Buenos Aires, Argentina
- Research Site
-
Cordoba, Argentina
- Research Site
-
Corrientes, Argentina
- Research Site
-
-
Buenos Aires
-
Cap. Fed., Buenos Aires, Argentina
- Research Site
-
Ciudad de Buenos Aires, Buenos Aires, Argentina
- Research Site
-
-
Santa Fe-argentina
-
Rosario, Santa Fe-argentina, Argentina
- Research Site
-
-
-
-
New South Wales
-
Liverpool, New South Wales, Australia
- Research Site
-
New Lambton Heights, New South Wales, Australia
- Research Site
-
-
Queensland
-
Chermside, Queensland, Australia
- Research Site
-
-
South Australia
-
Adelaide, South Australia, Australia
- Research Site
-
-
Western Australia
-
Perth, Western Australia, Australia
- Research Site
-
-
-
-
ES
-
Cariacica, ES, Brasil
- Research Site
-
Vitoria, ES, Brasil
- Research Site
-
-
GO
-
Goiania, GO, Brasil
- Research Site
-
-
MG
-
Uberlandia, MG, Brasil
- Research Site
-
-
MT
-
Cuiaba, MT, Brasil
- Research Site
-
-
PR
-
Curitiba, PR, Brasil
- Research Site
-
-
SP
-
Ribeirao Preto, SP, Brasil
- Research Site
-
Sao Paulo, SP, Brasil
- Research Site
-
-
-
-
-
Aalst, Bélgica
- Research Site
-
Brugge, Bélgica
- Research Site
-
Brussels, Bélgica
- Research Site
-
Charleroi, Bélgica
- Research Site
-
Genk, Bélgica
- Research Site
-
Leuven, Bélgica
- Research Site
-
-
-
-
-
Quebec, Canadá
- Research Site
-
-
Alberta
-
Calgary, Alberta, Canadá
- Research Site
-
Edmonton, Alberta, Canadá
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canadá
- Research Site
-
Victoria, British Columbia, Canadá
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá
- Research Site
-
-
New Brunswick
-
Saint John, New Brunswick, Canadá
- Research Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canadá
- Research Site
-
London, Ontario, Canadá
- Research Site
-
Newmarket, Ontario, Canadá
- Research Site
-
Ottawa, Ontario, Canadá
- Research Site
-
Toronto, Ontario, Canadá
- Research Site
-
-
Quebec
-
Chicoutimi, Quebec, Canadá
- Research Site
-
Laval, Quebec, Canadá
- Research Site
-
Montreal, Quebec, Canadá
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá
- Research Site
-
-
-
-
Andalucia
-
Malaga, Andalucia, España
- Research Site
-
-
Asturias
-
Oviedo, Asturias, España
- Research Site
-
-
Cataluna
-
Badalona, Cataluna, España
- Research Site
-
Barcelona, Cataluna, España
- Research Site
-
-
Comunidad Valenciana
-
Alicante, Comunidad Valenciana, España
- Research Site
-
-
Comunidad de Madrid
-
Madrid, Comunidad de Madrid, España
- Research Site
-
-
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos
- Research Site
-
-
California
-
Los Angeles, California, Estados Unidos
- Research Site
-
Mountain View, California, Estados Unidos
- Research Site
-
Sacramento, California, Estados Unidos
- Research Site
-
San Diego, California, Estados Unidos
- Research Site
-
Santa Rosa, California, Estados Unidos
- Research Site
-
Torrance, California, Estados Unidos
- Research Site
-
-
Colorado
-
Boulder, Colorado, Estados Unidos
- Research Site
-
Greeley, Colorado, Estados Unidos
- Research Site
-
Loveland, Colorado, Estados Unidos
- Research Site
-
-
Connecticut
-
Farmington, Connecticut, Estados Unidos
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos
- Research Site
-
-
Florida
-
Clearwater, Florida, Estados Unidos
- Research Site
-
Ft Lauderdale, Florida, Estados Unidos
- Research Site
-
Jacksonville, Florida, Estados Unidos
- Research Site
-
Melbourne, Florida, Estados Unidos
- Research Site
-
Miami, Florida, Estados Unidos
- Research Site
-
Orlando, Florida, Estados Unidos
- Research Site
-
Sarasota, Florida, Estados Unidos
- Research Site
-
Tampa, Florida, Estados Unidos
- Research Site
-
Winter Haven, Florida, Estados Unidos
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos
- Research Site
-
Augusta, Georgia, Estados Unidos
- Research Site
-
-
Indiana
-
Elkhart, Indiana, Estados Unidos
- Research Site
-
Hammond, Indiana, Estados Unidos
- Research Site
-
Indianapolis, Indiana, Estados Unidos
- Research Site
-
Merrillville, Indiana, Estados Unidos
- Research Site
-
Valparaiso, Indiana, Estados Unidos
- Research Site
-
-
Iowa
-
Davenport, Iowa, Estados Unidos
- Research Site
-
Iowa City, Iowa, Estados Unidos
- Research Site
-
West Des Moines, Iowa, Estados Unidos
- Research Site
-
-
Kentucky
-
Ashland, Kentucky, Estados Unidos
- Research Site
-
Lexington, Kentucky, Estados Unidos
- Research Site
-
Louisville, Kentucky, Estados Unidos
- Research Site
-
-
Louisiana
-
Covington, Louisiana, Estados Unidos
- Research Site
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos
- Research Site
-
Columbia, Maryland, Estados Unidos
- Research Site
-
Takoma Park, Maryland, Estados Unidos
- Research Site
-
-
Michigan
-
Bay City, Michigan, Estados Unidos
- Research Site
-
Grand Blanc, Michigan, Estados Unidos
- Research Site
-
Kalamazoo, Michigan, Estados Unidos
- Research Site
-
Midland, Michigan, Estados Unidos
- Research Site
-
Muskegon, Michigan, Estados Unidos
- Research Site
-
Petoskey, Michigan, Estados Unidos
- Research Site
-
Saginaw, Michigan, Estados Unidos
- Research Site
-
Southfield, Michigan, Estados Unidos
- Research Site
-
-
Minnesota
-
Duluth, Minnesota, Estados Unidos
- Research Site
-
Minneapolis, Minnesota, Estados Unidos
- Research Site
-
Rochester, Minnesota, Estados Unidos
- Research Site
-
St Cloud, Minnesota, Estados Unidos
- Research Site
-
St. Paul, Minnesota, Estados Unidos
- Research Site
-
-
Missouri
-
Columbia, Missouri, Estados Unidos
- Research Site
-
Kansas City, Missouri, Estados Unidos
- Research Site
-
-
Montana
-
Missoula, Montana, Estados Unidos
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos
- Research Site
-
Omaha, Nebraska, Estados Unidos
- Research Site
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos
- Research Site
-
Ridgewood, New Jersey, Estados Unidos
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos
- Research Site
-
-
New York
-
Buffalo, New York, Estados Unidos
- Research Site
-
Johnson City, New York, Estados Unidos
- Research Site
-
New York, New York, Estados Unidos
- Research Site
-
Roslyn, New York, Estados Unidos
- Research Site
-
Williamsville, New York, Estados Unidos
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos
- Research Site
-
Gastonia, North Carolina, Estados Unidos
- Research Site
-
Greensboro, North Carolina, Estados Unidos
- Research Site
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos
- Research Site
-
Cleveland, Ohio, Estados Unidos
- Research Site
-
Columbus, Ohio, Estados Unidos
- Research Site
-
Elyria, Ohio, Estados Unidos
- Research Site
-
Kettering, Ohio, Estados Unidos
- Research Site
-
Middleburg Heights, Ohio, Estados Unidos
- Research Site
-
Perrysburg, Ohio, Estados Unidos
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos
- Research Site
-
Tulsa, Oklahoma, Estados Unidos
- Research Site
-
-
Oregon
-
Bend, Oregon, Estados Unidos
- Research Site
-
Eugene, Oregon, Estados Unidos
- Research Site
-
Hillsboro, Oregon, Estados Unidos
- Research Site
-
-
Pennsylvania
-
Danville, Pennsylvania, Estados Unidos
- Research Site
-
Doylestown, Pennsylvania, Estados Unidos
- Research Site
-
Hershey, Pennsylvania, Estados Unidos
- Research Site
-
Philadelphia, Pennsylvania, Estados Unidos
- Research Site
-
Wormleysburg, Pennsylvania, Estados Unidos
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos
- Research Site
-
Germantown, Tennessee, Estados Unidos
- Research Site
-
Knoxville, Tennessee, Estados Unidos
- Research Site
-
Memphis, Tennessee, Estados Unidos
- Research Site
-
Oak Ridge, Tennessee, Estados Unidos
- Research Site
-
-
Texas
-
Dallas, Texas, Estados Unidos
- Research Site
-
San Antonio, Texas, Estados Unidos
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos
- Research Site
-
-
Washington
-
Bellevue, Washington, Estados Unidos
- Research Site
-
Spokane, Washington, Estados Unidos
- Research Site
-
Tacoma, Washington, Estados Unidos
- Research Site
-
-
-
-
-
Moscow, Federación Rusa
- Research Site
-
Saint Petersburg, Federación Rusa
- Research Site
-
Tomsk, Federación Rusa
- Research Site
-
Tumen, Federación Rusa
- Research Site
-
-
Moscow Region
-
Krasnogorsk, Moscow Region, Federación Rusa
- Research Site
-
-
-
-
-
Besancon, Francia
- Research Site
-
Bron, Francia
- Research Site
-
Creteil, Francia
- Research Site
-
Le Plessis-robinson, Francia
- Research Site
-
Marseille, Francia
- Research Site
-
Pessac, Francia
- Research Site
-
Quincy Sous Senart, Francia
- Research Site
-
Strasbourg, Francia
- Research Site
-
Toulouse, Francia
- Research Site
-
-
-
-
-
Budapest, Hungría
- Research Site
-
Szged, Hungría
- Research Site
-
-
-
-
-
Novara, Italia
- Research Site
-
Roma, Italia
- Research Site
-
-
AR
-
Arezzo, AR, Italia
- Research Site
-
-
MI
-
Milano, MI, Italia
- Research Site
-
Rozzano, MI, Italia
- Research Site
-
-
Milano
-
Sesto San Giovanni, Milano, Italia
- Research Site
-
-
PR
-
Parma, PR, Italia
- Research Site
-
-
SI
-
Siena, SI, Italia
- Research Site
-
-
UD
-
Udine, UD, Italia
- Research Site
-
-
-
-
-
Aguascalientes, México
- Research Site
-
D.F, México
- Research Site
-
Monterrey, México
- Research Site
-
Puebla, México
- Research Site
-
Queretaro, México
- Research Site
-
Tijuana, México
- Research Site
-
-
Jalisco
-
Guadalajara, Jalisco, México
- Research Site
-
-
-
-
-
Alkmaar, Países Bajos
- Research Site
-
Amsterdam, Países Bajos
- Research Site
-
Breda, Países Bajos
- Research Site
-
Eindhoven, Países Bajos
- Research Site
-
Enschede, Países Bajos
- Research Site
-
Leeuwarden, Países Bajos
- Research Site
-
Nieuwegein, Países Bajos
- Research Site
-
Nijmegen, Países Bajos
- Research Site
-
Rotterdam, Países Bajos
- Research Site
-
Zwolle, Países Bajos
- Research Site
-
-
-
-
-
Bialystok, Polonia
- Research Site
-
Katowice, Polonia
- Research Site
-
Kedzierzyn Kozle, Polonia
- Research Site
-
Krakow, Polonia
- Research Site
-
Lodz, Polonia
- Research Site
-
Poznan, Polonia
- Research Site
-
Warszawa, Polonia
- Research Site
-
Zabrze, Polonia
- Research Site
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 75 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Clinical indication for coronary angiography
- Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1 lesion in a native coronary artery that has >20% reduction in lumen diameter by visual estimation
- Left main coronary artery must have <=50% reduction in lumen diameter by visual estimation
- LDL-C >100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks; LDL-C >80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks
Exclusion Criteria:
- Use of certain lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis.
- Patients who have symptoms consistent with moderate or greater severity of Congestive Heart Failure (CHF).
- Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Rosuvastatin 20 mg
Rosuvastatin 20 mg distributed in 2-week run-in period
|
capsule, oral, once daily
Otros nombres:
|
Comparador activo: Atorvastatin 40 mg
Atorvastatin 40 mg distributed in 2-week run-in period
|
capsule, oral, one daily
Otros nombres:
|
Experimental: Rosuvastatin 40 mg
Rosuvastatin 40 mg distributed in core 2-year study
|
capsule, oral, once daily
Otros nombres:
|
Comparador activo: Atorvastatin 80 mg
Atorvastatin 80 mg distributed in core 2-year study
|
capsule, oral, one daily
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)
Periodo de tiempo: End of study (Week 104)
|
Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as: [sum(EEMcsa-LUMENcsa)/sum EEMcsa]*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD. |
End of study (Week 104)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Numbers of Patients Showing Regression in PAV
Periodo de tiempo: End of study (Week 104)
|
Regression defined as a change from baseline in PAV < 0
|
End of study (Week 104)
|
Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)
Periodo de tiempo: End of study (Week 104)
|
Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n.
n is the number of cross-sections measured.
TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.
|
End of study (Week 104)
|
Numbers of Patients Showing Regression in TAV
Periodo de tiempo: End of study (Week 104)
|
Regression defined as a change from baseline in TAV < 0
|
End of study (Week 104)
|
Total Cholesterol Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
LDL-C Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
HDL-C Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Triglycerides Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Non-HDL-C Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
LDL-C/HDL-C Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Total Cholesterol/HDL-C Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Non-HDL-C/HDL-C Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Apolipoprotein B Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Apolipoprotein A-1 Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Apoliprotein B/Apolipoprotein A-1 Blood Level
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
VLDL-C During the 104 Week Treatment Period
Periodo de tiempo: 104 weeks
|
Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.
|
104 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Stephen J Nicholls, MBBS, PhD, Cleveland Clinic Foundation, Cardiovascular Medicine
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging. 2014 Oct;7(10):1013-22. doi: 10.1016/j.jcmg.2014.04.019. Epub 2014 Sep 17.
- Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr;15(4):380-8. doi: 10.1093/ehjci/jet251. Epub 2014 Jan 20.
- Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013 Nov 26;128(22):2395-403. doi: 10.1161/CIRCULATIONAHA.113.004243. Epub 2013 Sep 16.
- Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de enero de 2008
Finalización primaria (Actual)
1 de junio de 2011
Finalización del estudio (Actual)
1 de junio de 2011
Fechas de registro del estudio
Enviado por primera vez
6 de febrero de 2008
Primero enviado que cumplió con los criterios de control de calidad
20 de febrero de 2008
Publicado por primera vez (Estimar)
21 de febrero de 2008
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
16 de julio de 2012
Última actualización enviada que cumplió con los criterios de control de calidad
11 de julio de 2012
Última verificación
1 de julio de 2012
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades cardíacas
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Enfermedad coronaria
- Enfermedad de la arteria coronaria
- Isquemia miocardica
- Aterosclerosis
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Antimetabolitos
- Agentes Anticolesterolémicos
- Agentes hipolipidémicos
- Agentes reguladores de lípidos
- Inhibidores de la hidroximetilglutaril-CoA reductasa
- Atorvastatina
- Rosuvastatina Cálcica
Otros números de identificación del estudio
- D356IC00001
- 2007-004000-13
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Rosuvastatin
-
EMSAún no reclutandoDiabetes mellitus tipo 2 | Dislipidemia
-
EMSReclutamientoDislipidemia asociada a diabetes mellitus tipo IIBrasil